Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Durlobactam (DUR; ETX2514) is a novel β-lactamase inhibitor with broad-spectrum activity against Ambler class A, C, and D β-lactamases. Durlobactam restores the in vitro activity of sulbactam (SUL) against members of the Acinetobacter baumannii-A. calcoaceticus complex (ABC). Sulbactam (SUL)-durloba...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrob Agents Chemother
Hauptverfasser: Sagan, Olexiy, Yakubsevitch, Ruslan, Yanev, Krassimir, Fomkin, Roman, Stone, Emily, Hines, Daniel, O’Donnell, John, Miller, Alita, Isaacs, Robin, Srinivasan, Subasree
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2020
Schlagworte:
Clinical Therapeutics
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7038258/
https://ncbi.nlm.nih.gov/pubmed/31843995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01506-19
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge